# Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Canonical URL: https://biopharmsignal.com/news/CNTA/lilly-to-acquire-centessa-pharmaceuticals-to-advance-treatments-for-sleep-wake-disorders
Ticker: CNTA
Company: Centessa Pharmaceuticals
Source: Centessa Pharmaceuticals
Published: 2026-03-31 10:45 EST
Original Source URL: https://investors.centessa.com
## Summary

Centessa's OX2R agonist pipeline includes a potential best-in-class therapeutic with significant promise to meaningfully improve outcomes across a range of sleep-wake disorders Acquisition expands Lilly's neuroscience portfolio and capabilities into sleep medicine INDIANAPOLIS and BOSTON and

## Article Body
Centessa's OX2R agonist pipeline includes a potential best-in-class therapeutic with significant promise to meaningfully improve outcomes across a range of sleep-wake disorders Acquisition expands Lilly's neuroscience portfolio and capabilities into sleep medicine INDIANAPOLIS and BOSTON and
## Recent Company News
- 2026-03-31 10:45 EST — [Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders](https://biopharmsignal.com/news/CNTA/lilly-to-acquire-centessa-pharmaceuticals-to-advance-treatments-for-sleep-wake-disorders) — Source: Centessa Pharmaceuticals
- 2026-02-03 13:00 EST — [Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-to-participate-in-upcoming-investor-conferences) — Source: Centessa Pharmaceuticals
- 2026-01-14 22:00 EST — [Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting](https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-announces-poster-presentation-of-new-preclinical-data-supporting-expansion-of-orexin-receptor-2-ox2r-agonist-pipeline-into-neuropsychiatric-indications-at-the-64th-acnp-annual-meeting) — Source: Centessa Pharmaceuticals
- 2025-12-11 12:00 EST — [Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications](https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-announces-ceo-transition-as-company-advances-strategy-to-extend-orexin-leadership-into-multiple-neuroscience-indications) — Source: Centessa Pharmaceuticals
- 2025-11-12 01:40 EST — [Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares](https://biopharmsignal.com/news/CNTA/centessa-pharmaceuticals-announces-pricing-of-250-000-000-public-offering-of-american-depositary-shares) — Source: Centessa Pharmaceuticals
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)